Case Evaluation
Over $150 Million Collected for Plantiffs in 2011

Pradaxa Internal Bleeding

Pradaxa was officially approved in Europe by the EMA on March 18, 2008 and in the United States by the FDA on October 19, 2010.

In only a few years this drug, an anticoagulant prescribed to patients suffering from atrial fibrillation, has been prescribed millions of times in order to help prevent serious blood clots and strokes.

However, there have been recent reports that indicate taking this drug may cause serious or fatal Pradaxa internal bleeding.

After only weeks of the drug's approval, the FDA had linked Pradaxa to more adverse effects than over 98% of other drugs on the market. Some of the dangerous and even potentially deadly side effects that this drug may cause are:

  • Massive internal bleeding
  • Hemorrhaging of the gastrointestinal system
  • Hemorrhaging of the brain
  • Hemorrhaging of the kidneys
  • An increased risk of heart attack

The FDA is also conducting an investigation as to whether Boehringer Ingelheim, the manufacturer of Pradaxa, had previous knowledge of the serious side effects of the drug such as Pradaxa internal bleeding, and failed to properly warn patients.

In the meantime, those who may have been injured as well as their families are able to seek recovery for their loss through taking legal action.

If you or someone you love suffered an injury or death after taking Pradaxa, it is important to learn your legal options as soon as possible. You may be entitled to substantial compensation; however, the time to act is limited. Contact us today.

 A qualified lawyer will be able to explain to you the evidence of this drug's serious health risks as well as whether the maker of Pradaxa had previous knowledge of the drug's propensity to cause Pradaxa internal bleeding.

In November 2011, Boehringer Ingelheim confirmed over 250 reports of death caused from fatal bleeding in patients taking Pradaxa.  There are many experts who are questioning why the drug was even approved in the first place.

There are other anticoagulants like Coumadin and Wayfarin that have the propensity to cause internal bleeding; however, this can usually be controlled by the administration of PCC (prothrombin complex concentrate), Vitamin K as well as fresh frozen plasma.

Unfortunately, with the internal bleeding caused from Pradaxa there is no reversal agent. This means that once a Pradaxa internal bleeding event begins in a patient, there is very little doctors can do to stop it.

In a report in the Journal of Neurosurgery on March 6, 2012, there was a detailed account of an atrial fibrillation patient who suffered a low level fall and died from massive internal bleeding. The patient had recently begun taking Pradaxa and doctors were unable to stop the bleeding because of the fact that there is no reversal agent for this drug.

Qualified attorneys with the Pradaxa Litigation Group have helped thousands of victims and their families file lawsuits and recovered compensation after a defective drug injury. These same lawyers are available to help with your case today.

Before you put your trust in a lawyer, make sure they are qualified to handle this type of case and have experience fighting large drug companies.

The Pradaxa Resource Center works with only the top defective drug law firms in the country to make sure your case is handled properly and efficiently. Contact us today to learn more about the health warnings and current litigation involving Pradaxa. We are available 24 hours a day to answer your questions and provide you with help.

Facebook Twitter Youtube